Our investigation confirms the biologic and prognostic significance of the tumor immune microenvironment for patients with stage I lung ADC and provides support for its use to stratify clinical outcome and immunotherapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2012) studied this question.